Why the study?
Is donepezil associated with QTc prolongation and Torsades de Pointes in elderly patients with dementia?
Is donepezil associated with QTc prolongation and Torsades de Pointes in elderly patients with dementia?
Donepezil use in elderly dementia patients may be associated with a rare risk of QTc prolongation and Torsades de Pointes, which typically resolves upon drug discontinuation.
May support QTc monitoring with donepezil in elderly dementia; leaves open need for prospective confirmation before practice change.
Dementia can be seen as a clinical syndrome featuring a decline in cognitive and psychological abilities that can cause disability. Two major kinds of drugs are available: N-methyl-D-aspartic acid receptor antagonists like memantine and acetylcholinesterase inhibitors such as galantamine, rivastigmine and donepezil. In this article, we have reviewed the available literature along with the provision of a snapshot of published cases in the literature We used the PubMed database for our search. The average age of patients was 80 years and above. Patients described in the literature belonged to both female and male gender, with female patients being predominant. Patients demonstrated associated atrioventricular (AV) block or ventricular premature contractions (VPC) or atrial fibrillation (AF) prior to developing torsades de pointes (TdP). Presenting complaints were either syncope or diarrhoea or accidental bradycardia. Mostly, the corrected QT interval (QTc) normalisation was associated with discontinuation of donepezil. We recommend further studies to determine this correlation between donepezil and incidence of QTc prolongation and TdP.
No takes yet. Share an insight, caveat, or question.
Malik et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: